Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2021

Nov 08, 2023

SELL
$5.03 - $8.8 $4.25 Million - $7.43 Million
-844,600 Reduced 65.71%
440,800 $2.74 Million
Q4 2020

Nov 08, 2023

BUY
$4.04 - $5.31 $5.19 Million - $6.83 Million
1,285,400 New
1,285,400 $6.29 Million
Q3 2020

Nov 08, 2023

BUY
$3.64 - $7.76 $669,032 - $1.43 Million
183,800 Added 17.01%
1,264,100 $5.32 Million
Q2 2020

Nov 08, 2023

BUY
$4.78 - $8.26 $271,026 - $468,342
56,700 Added 5.54%
1,080,300 $7.48 Million
Q1 2020

Nov 08, 2023

BUY
$4.0 - $21.53 $117,600 - $632,982
29,400 Added 2.96%
1,023,600 $4.09 Million
Q4 2019

Nov 08, 2023

BUY
$13.94 - $24.12 $11.6 Million - $20.1 Million
833,100 Added 517.13%
994,200 $21.3 Million
Q3 2019

Nov 08, 2023

BUY
$13.89 - $23.16 $2.24 Million - $3.73 Million
161,100 New
161,100 $2.44 Million

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $177M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.